46 results about "Hemoglobin levels" patented technology

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

Disclosed herein are systems, methods, computer-readable media, and techniques for determining health indicators from images taken using a non-augmented mobile device. Methods are presented for processing images comprising the lower eyelid portion of an eye and determining levels of said health indicators using one or more machine learning algorithms. One such health indicator is hemoglobin, the level of which can be used to determine at least indications of general health or presence of an anemia condition in a subject.

The present disclosure relates to systems, devices, and methods for measuring analyte levels. A glycosylated hemoglobin level measurement system includes a sample test cartridge having microchannels that can passively transfer and compress cells. The system may execute one or more calibration or normalization routines on the sensor data to generate calibrated or normalized data. The calibrated or normalized data may be used to determine one or more analyte levels.

A wearable diagnostic device that is worn on a user's body and is capable of providing various types of health-related information to the user is described. The wearable diagnostic device is capable of providing real-time, non-invasive, accurate, and continuous data about the user's heart rate, hemoglobin level, body temperature, oxygen level, glucose level, and blood pressure. In some embodiments, the wearable diagnostic device can also provide electrocardiogram (EKG) data or detection of Parkinson's symptoms, such as involuntary movements of the user's hands. The user can configure the wearable diagnostic device to provide information about one, more, or all of the health-related information listed above.

Disclosed herein is the use of a HIF-1α inhibitor for preventing, delaying or treating diabetes mellitus in a subject. The subject is susceptible to, or has diabetes mellitus and has elevated non-fasting blood glucose, and / or elevated fasting blood glucose, and / or impaired glucose tolerance and / or elevated hemoglobin A1c levels. In particular, the present disclosure relates to the use of a HIF-1α inhibitor, wherein the HIF-1α inhibitor is administered to the subject, thereby maintaining or providing increased non-fasting plasma insulin levels in said subject.

The invention belongs to the technical field of medicines, and relates to an application of a pharmaceutical composition in preparation of medicines for preventing and / or treating type II diabetes mellitus. The invention provides an application of a pharmaceutical composition in preparation of a medicine for preventing and / or treating type II diabetes mellitus. The pharmaceutical composition comprises the following components: ginsenoside Rk1, ginsenoside Rg5, ginsenoside Rg3, ginsenoside Rh4, ginsenoside Rk3, a ginseng ethanol-water extract and a pharmaceutically acceptable carrier. The pharmaceutical composition component provided by the invention can effectively reduce blood sugar and / or reduce the glycosylated hemoglobin level, and prevent and / or treat type II diabetes mellitus.

To provide dosing regimens for administering a HIF prolyl hydroxylase inhibitor in the treatment or prevention of anemia, such as anemia secondary to or associated with chronic kidney disease, or anemia associated with or resulting from chemotherapy.SOLUTION: A pharmaceutical composition in a form of a tablet or capsule comprising Compound 1 having the following structure, for use in a method of increasing hemoglobin levels in a patient in need thereof relative to a baseline hemoglobin level, wherein the patient has a hemoglobin level of ≤10.5 g / dL or ≥9.5 g / dL and ≤12 g / dL at a start of treatment, a serum hemoglobin level increases by at least about 0.1 to about 1.0 g / dL relative to the baseline hemoglobin level, and the pharmaceutical composition is used such that Compound 1 is administered to the patient once daily, for example at a dose of about 150 mg.SELECTED DRAWING: Figure 1a

This disclosure relates to a method and device for determining the hemoglobin level of a mammal. The device includes several light-emitting diodes, one or more sensors, and a processor.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

The present invention provides a pharmaceutical composition for use in a method of treating pulmonary arterial hypertension (PAH). [Solution] A pharmaceutical composition for use in a method for treating pulmonary arterial hypertension (PAH) in a patient in need, comprising an ActRIIA fusion protein, wherein the ActRIIA fusion protein is (i) ActRIIA polypeptide containing a specific amino acid sequence, (ii) Fc domains containing an amino acid sequence that is at least 95% identical to a specific amino acid sequence, (iii) comprising a linker domain located between the ActRIIA polypeptide and the Fc domain, Herein, the ActRIIA fusion protein is administered in a first dose of 0.3 mg / kg and a second dose of 0.7 mg / kg, wherein the second dose is administered after confirming that the patient has an acceptable hemoglobin level and / or platelet count, in a pharmaceutical composition.

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The invention provides a construction method of a mouse model for inducing acute inflammatory anemia. An existing inflammatory anemia model is too long in construction period and cannot simulate the clinical phenomenon of acute anemia, the mouse model provided by the invention can induce the number of red blood cells and the hemoglobin level to be remarkably reduced through single Poly (I: C) stimulation for 36 hours, an acute anemia time window is accurately simulated, and a good foundation is laid for mechanism research of acute inflammatory anemia.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

A wearable, skin adhesive blood gas monitoring device detects both oxygen and carbon dioxide for accommodating a potential inaccuracy in an oxygen level resulting from excessive carbon dioxide. Photoluminescent films in conjunction with a compact form-factor circuit provide a wearable and unobtrusive device that adheres directly to the epidermal surface for computation of blood gas levels based on transcutaneous and reflective properties of the blood gases. A wireless medium such as Bluetooth® enables communication to a standalone or portable device such as a smartphone or similar personal device having an application (app) for receiving the computed signals. Conditions such as hypercarbia, which tend to result in higher levels of carbaminohemoglobin, or hemoglobin bound to CO2 instead of oxygen, tend to compromise computed oxygen levels by interpreting the CO2-bound hemoglobin as oxygenated blood.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.

The disclosure is directed to a method of replenishing a subject's iron, ferritin, and / or hemoglobin level. The method includes orally administering elemental metal iron to the subject; and orally administering a source of nitrate anion to the subject.

The present invention relates to a device and a method for determining the hematocrit and / or hemoglobin level of a liquid flowing in a tubular portion (2), the method comprising: emitting a light beam in the direction of the tubular portion (2) with at least two light sources (11; 21), each of the two light sources (11; 21) being configured to emit a light beam at an emission wavelength selected to correspond to the isosbestic point of hemoglobin; receiving light signals transmitted through the tubular portion (2) with at least two light sensors (12; 22), each light sensor (12; 22) being associated with one of the two light sources (11; 21); calculating the hematocrit or hemoglobin level in the liquid by processing the light signals received by the light sensors (12; 22); characterized in that, when determining the hematocrit level and / or hemoglobin level, the emission power of at least one light source (11; 21) is adjusted according to the calculated hematocrit and / or corresponding hemoglobin level of the liquid.

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

The invention relates to the technical field of medical artificial intelligence, and particularly discloses a method for establishing a disease prediction model of GCK-MODY in gestational diabetes population based on machine learning. The model takes five clinical characteristics as input variables: a body mass index before pregnancy, fasting blood glucose and glycosylated hemoglobin levels during GDM diagnosis, continuous multi-generation diabetes family history and a newly discovered predictive factor, namely GDM diagnosis week of pregnancy. A classification model is constructed through a support vector machine algorithm, and a SHapley additive interpretation method is adopted to provide global and local interpretation of a prediction result, so that model transparency is enhanced. The area of the model under a curve in a test is obviously superior to that of an existing screening standard. The invention also provides an electronic device, a storage medium and a prediction system comprising the model, which can assist clinicians in early recognition of GCK-MODY high-risk patients, provide decision support for targeted gene detection, avoid unnecessary enhanced hypoglycemic treatment of pregnant women, reduce the risk of maternal and infant complications, and promote precise medical development of gestational diabetes mellitus.

The application discloses a traditional Chinese medicine composition, preparation and application for treating type 2 diabetes and / or promoting remission of metabolic syndrome mainly caused by abnormal blood sugar. The composition comprises Fushen, Huanglian, Shengshigao, Tianhuafen, Zhimu, Fangji and Gegen, and selectively contains Shengjiang. The composition can reduce the fasting blood sugar, 2h postprandial blood sugar and glycosylated hemoglobin level of a type 2 diabetes patient, improve insulin resistance and promote physiological secretion of insulin, thereby being used for treating type 2 diabetes and promoting remission of type 2 diabetes. Meanwhile, the composition can comprehensively reduce blood pressure, regulate blood fat, reduce body weight and waist circumference and comprehensively correct metabolic syndrome; the composition has no obvious liver and kidney toxicity and has a liver function protection effect, and therefore has high safety.

The application provides a mouse model construction method for inducing acute inflammatory anemia. The existing inflammatory anemia model construction cycle is too long, and the clinical phenomenon of acute anemia cannot be simulated. The mouse model provided by the application can induce a significant decrease in the number of red blood cells and the level of hemoglobin by single Poly (I:C) stimulation for 36 hours, accurately simulates the time window of acute anemia, and lays a good foundation for the mechanism research of acute inflammatory anemia.

Provided herein are methods of treating sickle cell disease, methods of increasing hemoglobin levels in a subject diagnosed with sickle cell disease, and methods of reducing hemolysis-associated complications in a subject diagnosed with sickle cell disease, together with kits for such treatments, in a subject in need thereof, comprising administering a Gardos channel inhibitor such as 2,2-bis(4-fluorophenyl)-2-phenylacetamide and a pyruvate kinase activator such as N-(4-((4-(Cyclopropylmethyl)-1-piperazinyl)carbonyl)phenyl)-8- quinolinesulfonamide to the subject. Subjects eligible for treatment include subjects as having hemolysis dominant (HD) sickle cell disease on the basis of laboratory markers, clinical history, and / or sequelae.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a qi-tonifying and blood-maintaining preparation in preparation of a medicine for treating thalassemia. Researches show that the preparation for tonifying qi and maintaining blood is used for treating thalassemia and can effectively improve the anemia state and iron metabolism disorder of patients. Specifically, the medicine can significantly improve the hemoglobin level, increase the red blood cell count and the red blood cell average volume, and improve the serum iron content, the ferritin content and the reticulocyte proportion. The results show that the qi-tonifying and blood-maintaining preparation has the effect of promoting the bone marrow hematopoiesis function and can regulate and optimize the iron metabolism process. The invention provides an economical, effective and convenient treatment scheme for the thalassemia patient.

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

Systems and methods for detecting cognitive disorders are disclosed. The head-mounted sensor may be worn by a user. The head-mounted sensor includes an optical sensor for collecting an optical response from a region of interest in the user's brain. The user input interface receives a user test input from a test device for performing a stimulation test on a user. The controller is coupled to the sensor device and the user input interface. A controller collects optical response data from the optical sensor and test input data from the test device. The controller determines a hemoglobin level in the region of interest from the optical response data. The determined hemoglobin level in the region of interest is associated with a user test input in response to the stimulation test. Brain activity is evaluated based on the determined hemoglobin level.

The present invention discloses the use of methyl α-D-glucopyranoside in the preparation of thalassemia therapeutic drugs. Comprehensive analysis shows that when methyl α-D-glucopyranoside was intraperitoneally injected into β-thalassemia mice, it was found that methyl α-D-glucopyranoside was one of the metabolites with the largest down-regulation amplitude, and had multiple beneficial effects on Th3 / + mice, including increasing the total red blood cell count, hemoglobin level and hematocrit, and reducing the coefficient of variation of the red blood cell volume distribution width; reducing the iron content in the liver, splenomegaly and iron content in the spleen; increasing the GSH / GSSG ratio, reducing the ROS level, reducing the apoptosis rate of peripheral blood cells, and increasing the lifespan of red blood cells. After GP treatment, the ineffective hematopoiesis, anemia and iron overload of thalassemia mice were effectively alleviated without obvious toxic side effects. The treatment is convenient to implement, and GP is cheap and easy to store.

Methods and apparatus for multi-wavelength (MW) photoplethysmography (PPG)-based trend monitoring are used to monitor changes in total hemoglobin, fluid accumulation in circulation (plasma volume) and tissues (interstitial fluid volume), total blood volume, and tissue perfusion (microcirculation). The methods and systems provide integration of automated decision support in both medical-grade and non-medical grade wearables for continuous body fluid management guided by MW PPG measurements. Recommendations for optimizing physiological function, including management of fluid intake, restriction or removal, co-administration of cardiovascular medication, and red blood cell transfusion may be provided. Blood loss detection and transfusion-related recommendations may be made based in assessing whole-body hemoglobin mass changes by differentiating dilution-related variations in hemoglobin concentration from net changes in hemoglobin mass due to red blood cell loss or transfusion. Plasma dilution-related fluctuations in plasma volume and corresponding blood volume changes may also be monitored alongside fluctuations in tissue fluid volume and transcapillary fluid shifts. The system may provide clinically relevant trend data for clinician interpretation and real-time alerts for assessing fluid status, including intravascular and extravascular fluid accumulation, total blood volume changes, plasma volume, and net hemoglobin mass variations. Clinical guidance on fluid management, real-time alerts for imminent edema or dehydration risks, and notifications regarding potential blood loss or transfusion effects on hemoglobin levels may be provided. In a non-clinical setting, the system advises on fluid intake or restriction based on fluid accumulation trends in circulation and tissues which are an indication of plasma and tissue hydration status, and prompts users to seek medical attention when a significant reduction in hemoglobin is detected.

Methods and apparatus for multi -wavelength (MW) photoplethysmography (PPG)-based trend monitoring are used to monitor changes in total hemoglobin, fluid accumulation in circulation (plasma volume) and tissues (interstitial fluid volume), total blood volume, and tissue perfusion (microcirculation). The methods and systems provide integration of automated decision support in both medical-grade and non-medical grade wearables for continuous body fluid management guided by MW PPG measurements. Recommendations for optimizing physiological function, including management of fluid intake, restriction or removal, co-administration of cardiovascular medication, and red blood cell transfusion may be provided. Blood loss detection and transfusion- related recommendations may be made based in assessing whole-body hemoglobin mass changes by differentiating dilution-related variations in hemoglobin concentration from net changes in hemoglobin mass due to red blood cell loss or transfusion. Plasma dilution-related fluctuations in plasma volume and corresponding blood volume changes may also be monitored alongside fluctuations in tissue fluid volume and transcapillary fluid shifts. The system may provide clinically relevant trend data for clinician interpretation and real-time alerts for assessing fluid status, including intravascular and extravascular fluid accumulation, total blood volume changes, plasma volume, and net hemoglobin mass variations. Clinical guidance on fluid management, real-time alerts for imminent edema or dehydration risks, and notifications regarding potential blood loss or transfusion effects on hemoglobin levels may be provided. In a non-clinical setting, the system advises on fluid intake or restriction based on fluid accumulation trends in circulation and tissues which are an indication of plasma and tissue hydration status, and prompts users to seek medical attention when a significant reduction in hemoglobin is detected.